Have you worked on a Wikipedia article before? This is my first time and I am hoping this will be interesting.

Welcome!

edit

Hello, MadelineJuliette, and welcome to Wikipedia! Thank you for your contributions. I hope you like the place and decide to stay. Here are a few links to pages you might find helpful:

Please remember to sign your messages on talk pages by typing four tildes (~~~~); this will automatically insert your username and the date. If you need help, check out Wikipedia:Questions, ask me on my talk page, or click here to ask for help here on your talk page and a volunteer will visit you here shortly. Again, welcome! Gaff (talk) 00:02, 23 January 2015 (UTC)Reply

Maddy is the bomb.com

edit

Hey Mads! This is Spidey1994. I live in the same hall as you. I think you're pretty cool cause you're in AQ. Also I like your longish bangs. Love- your future roomie — Preceding unsigned comment added by Spidey1994 (talkcontribs) 01:56, 26 January 2015 (UTC)Reply

Introducing myself

edit

Hi MadelineJuliette. I work with the Wiki Education Foundation, and help support students who are editing as part of a class assignment. If there's anything I can do to help with your assignment (or, for that matter, any other aspect of Wikipedia) please feel free to drop me a note. Ian (Wiki Ed) (talk) 22:26, 5 February 2015 (UTC)Reply

Neuroferritinopathy

edit

Bibliography: Zecca, Luigi, et al. "Iron, Brain Ageing And Neurodegenerative Disorders." Nature Reviews Neuroscience 5.11 (2004): 863-873. Academic Search Complete. Web. 15 Feb. 2015. [1]

Woimant. Handbook Of Clinical Neurology Volume: 120 (2014-01-01) p. 851-864. [2]

Keogh, M J. International Review Of Neurobiology Volume: 110 (2013-01-01) p. 91-123. [3]

LEHN [4]

Signs/Symptoms and Epidemiology

edit

Signs and Symptoms

edit

Neuroferritinopathy has several distinguishing symptoms. The signs and symptoms that characterize Neuroferritinopathy fall into two categories: medically tested and diagnosed symptoms and physically visible symptoms.

Symptoms categorized as medically tested and diagnosed include iron accumulation in the brain, basal ganglia cavitation, and neurodegeneration.[5] Patients who are diagnosed with Neuroferritinopathy are always found to have an abnormal iron accumulation in the brain within the neurons and glia of the striatum and cerebellar cortexes.[6] Along with the accumulation of iron with the brain, Neuroferritinopathy typically causes severe neuronal loss as well.[7] It is a possibility that the iron accumulation in the brain is a consequence of neurodegeneration resulting in neuronal damage and loss of neurons.[8] The damaged neurons may be being substituted by cells with a higher iron content in an effort to reverse the neurodegeneration, or a breakdown of the blood brain barrier occurs due to the loss of neurons and is subsequently allowing more iron to access the brain over time.[9]

Neuroferritinopathy is mainly seen in those who have reached late adulthood and is generally seen to slowly progress throughout many decades in a lifetime with the mean age of onset being 39 years old.[10] Typically, a loss of cognition is generally only seen with late stages of the disease.[11] Diagnosed patients are seen to retain most of their cognitive functioning until the most progressive stages of the illness sets in.[12]

Symptoms categorized as physically visible symptoms include chorea, dystonia, spasticity, and rigidity, all physical symptoms of the body associated with movement disorders.[13] The symptoms accompanying Neuroferritinopathy affecting movement are also progressive, becoming more generalized with time.[14] Usually during the first ten years of onset of the disease only one or two limbs are directly affected.[15] Distinctive symptoms of Neuroferritinopathy are chorea, found in 50% of diagnosed patients, dystonia, found in 43% of patients, and Parkinsonism, found in 7.5% of patients.[16] Full control of upper limbs on the body generally remains until late onset of the disease.[17] Interestingly, over time, symptoms seen in a patient can change from one side of the body to the opposite side of the body, jumping from left to right or vice versa.[18] Another route that the physically visible symptoms have been observed to take is the appearance, disappearance, and then reappearance once more of specific symptoms.[19]

Epidemiology

edit

Neuroferritinopathy was first discovered in 2001, with its first case being reported in Cumbria from northern England.[20] The discovery of Neuroferritinopathy was mediated by a study done on a large family suffering from a dominantly inherited basal ganglia disease.[21] The disease was reported to be instigated by a mutation on the ferritin light chain polypeptide, (FTL1), and was found to cause iron accumulation in the brain and neurodegeneration.[22] Along with the first case of Neuroferritinopathy being located in northern England, the majority of patients diagnosed with the disease have also been found in northern and northeast England as well.[23] The localization of the majority of cases to northern and northeast England suggests that a common ancestor may be responsible for many or possibly all cases.[24] Despite there being fewer than 100 cases reported and the disease’s general location of northern and northeast England, multiple more cases of Neuroferritinopathy have been diagnosed around the rest of the world in recent years.[25]

References

  1. ^ Zecca, L; Youdim, MB; Riederer, P; Connor, JR; Crichton, RR (November 2004). "Iron, brain ageing and neurodegenerative disorders". Nature reviews. Neuroscience. 5 (11): 863–73. PMID 15496864.
  2. ^ Woimant, F; Trocello, JM (2014). "Disorders of heavy metals". Handbook of clinical neurology. 120: 851–64. PMID 24365357.
  3. ^ Keogh, MJ; Morris, CM; Chinnery, PF (2013). "Neuroferritinopathy". International review of neurobiology. 110: 91–123. PMID 24209436.
  4. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  5. ^ Keogh, MJ; Morris, CM; Chinnery, PF (2013). "Neuroferritinopathy". International review of neurobiology. 110: 91–123. PMID 24209436.
  6. ^ Zecca, L; Youdim, MB; Riederer, P; Connor, JR; Crichton, RR (November 2004). "Iron, brain ageing and neurodegenerative disorders". Nature reviews. Neuroscience. 5 (11): 863–73. PMID 15496864.
  7. ^ Zecca, L; Youdim, MB; Riederer, P; Connor, JR; Crichton, RR (November 2004). "Iron, brain ageing and neurodegenerative disorders". Nature reviews. Neuroscience. 5 (11): 863–73. PMID 15496864.
  8. ^ Zecca, L; Youdim, MB; Riederer, P; Connor, JR; Crichton, RR (November 2004). "Iron, brain ageing and neurodegenerative disorders". Nature reviews. Neuroscience. 5 (11): 863–73. PMID 15496864.
  9. ^ Zecca, L; Youdim, MB; Riederer, P; Connor, JR; Crichton, RR (November 2004). "Iron, brain ageing and neurodegenerative disorders". Nature reviews. Neuroscience. 5 (11): 863–73. PMID 15496864.
  10. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  11. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  12. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  13. ^ Zecca, L; Youdim, MB; Riederer, P; Connor, JR; Crichton, RR (November 2004). "Iron, brain ageing and neurodegenerative disorders". Nature reviews. Neuroscience. 5 (11): 863–73. PMID 15496864.
  14. ^ Keogh, MJ; Morris, CM; Chinnery, PF (2013). "Neuroferritinopathy". International review of neurobiology. 110: 91–123. PMID 24209436.
  15. ^ Keogh, MJ; Morris, CM; Chinnery, PF (2013). "Neuroferritinopathy". International review of neurobiology. 110: 91–123. PMID 24209436.
  16. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  17. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  18. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  19. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  20. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  21. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  22. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  23. ^ Lehn, A; Boyle, R; Brown, H; Airey, C; Mellick, G (September 2012). "Neuroferritinopathy". Parkinsonism & related disorders. 18 (8): 909–15. PMID 22818529.
  24. ^ Keogh, MJ; Morris, CM; Chinnery, PF (2013). "Neuroferritinopathy". International review of neurobiology. 110: 91–123. PMID 24209436.
  25. ^ Keogh, MJ; Morris, CM; Chinnery, PF (2013). "Neuroferritinopathy". International review of neurobiology. 110: 91–123. PMID 24209436.

Edit summaries

edit

Hi. When you're leaving feedback (or doing any other edits) don't forget to include an edit summary. It lets other editors know what your edit is about. Thanks! Ian (Wiki Ed) (talk) 15:42, 15 April 2015 (UTC)Reply